NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / India gets first nasal spray for COVID-19 treatment
    India gets first nasal spray for COVID-19 treatment
    India

    India gets first nasal spray for COVID-19 treatment

    Written by Sagar
    February 09, 2022 | 02:53 pm 2 min read
    India gets first nasal spray for COVID-19 treatment
    The DCGI has granted manufacturing and marketing approval for a COVID-19 nasal spray.

    Glenmark Pharmaceuticals has launched a nasal spray in India for the treatment of COVID-19 in adult patients. It has partnered with the Canadian pharmaceutical company SaNOtize Research & Development Corp. for the launch of the product, called FabiSpray. This comes after the Drugs Controller General of India (DCGI) granted manufacturing and marketing clearance to Glenmark as part of an accelerated approval procedure.

    Why does this story matter?

    Experts say nasal sprays and oral drugs against COVID-19 could be a gamechanger in the global fight against the pandemic. They are relatively easier to store, can be transported without refrigeration, and also remove injury risks that are associated with needle-based vaccines. Dr. Soumya Swaminathan, chief scientist at the World Health Organization, had earlier described such treatments as a "second generation" of coronavirus vaccines.

    How does the nasal spray work?

    FabiSpray, a Nitric Oxide Nasal Spray (NONS), is designed to "kill the coronavirus in the upper airways." It acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs, according to a company statement. It will be useful in the treatment of COVID-19 in patients who have a high risk of disease progression.

    99% viral load reduction in 48 hours

    Data from the phase-three trial conducted in India demonstrated a reduction of viral load by 94% in 24 hours and 99% in double of that time, the company claimed. It added the product was "safe and well-tolerated" among the volunteers involved in the trial. However, the data has yet to be published in a peer-reviewed journal.

    Europe, Israel have already cleared it

    The nasal spray has already received a CE mark from the European Union, which is an equivalent of marketing authorization. Besides, Bahrain and Israel have also cleared its sale. Robert Crockart of Glenmark Pharmaceuticals described it as "another safe and effective antiviral treatment." "We are confident it will offer patients a much-needed and timely therapy option," Crockart, the company's Chief Commercial Officer, said.

    COVID-19 situation in India

    On Wednesday, India added 71,365 new coronavirus infections, marking a surge of 5.5% from Tuesday's case count. The country's COVID-19 death toll has climbed to 5,05,279 with over 1,200 more related fatalities registered through Tuesday. Meanwhile, India has administered more than 170 crore COVID-19 vaccine doses so far. More than 75% of India's adult population has been fully vaccinated, as per government data.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    World Health Organization
    Coronavirus
    COVID-19

    World Health Organization

    New Omicron subvariant found in 57 countries, WHO says Coronavirus
    New Omicron subvariant spreads faster than original strain: Report India
    COVID-19 pandemic might end in Europe after Omicron's takeover: WHO Vaccine
    Will everyone get Omicron? Here's what WHO says COVID-19

    Coronavirus

    COVID-19: India reports over 1 lakh new cases; 865 deaths COVID-19
    Third wave to wane in Delhi, Maharashtra by February-end: ICMR Indian Council of Medical Research (ICMR)
    Omicron sub-variant BA.2: What do we know so far? World Health Organization
    COVID-19 vaccination, including boosters, 3 months after recovery: Centre Union Health Ministry

    COVID-19

    COVID-19 oral vaccine's clinical trial to begin in India soon Union Health Ministry
    COVID-19 restrictions in Mumbai to be lifted by month-end: Mayor Mumbai
    COVID-19: India logs 67,597 new cases; 1,188 fresh fatalities India
    Assam to lift COVID-19 curbs, night curfew from February 15 Assam
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023